Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Noradox
- Development stage
- Unknown
- Lead developer
- Errekappa Euroterapici
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Noradox is a small molecule pharmaceutical product containing doxazosin mesilate, marketed by Errekappa Euroterapici in Italy. It functions as a selective alpha-1 adrenergic receptor antagonist. By blocking these receptors, it induces peripheral vasodilation, effectively lowering blood pressure in patients with essential arterial hypertension. Additionally, it relaxes the smooth muscle in the prostate and bladder neck, which helps alleviate urinary symptoms associated with benign prostatic hyperplasia (BPH). Noradox is available as divisible tablets for oral administration.
- Brand names
- Noradox
- Other names
- doxazosindoxazosinadoxazosin mesilatedoxazosin mesylate
02
Targets
ADRA1A (α1A)
Beyond the preview
Go deeper on Noradox.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Noradox.